aCGH Impacts Survival in Plasma Cell PTLD

Array-CGH in Plasma Cell Post-transplantation Lymphoproliferative Disorders

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02984215

Enrollment

Registered

2016-12-06

Start date

1990-01-31

Completion date

2016-06-30

Last updated

2016-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-transplantation Lymphoproliferative Disorders

Brief summary

Plasma-cell post-transplantation lymphoproliferative disorders (PC-PTLD) are rare monomorphic PTLD divided into plasma cell myeloma (PCM) and plasmacytoma-like lesion (PLL) PTLD. To date, there is no exhaustive published cytogenetic data on PC-PTLD. The investigators report array-based comparative genomic hybridization (aCGH) of 10 cases of PCM and PLL-PTLD.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* WHO classification 2008 as monomorphic PCM (plasma cell myeloma) or PLL (plasmacytoma like lesion) / PTLD (post transplantation lymphoproliferative disorders).

Exclusion criteria

* Other than PCM or PLL PTLD at diagnosis

Design outcomes

Primary

Measure	Time frame
Genome wide array-based comparative genomic hybridization (aCGH)	At diagnosis of PTLD, Day 0.

Secondary

Measure	Time frame
Overall survival according to aCGH complexity	Overall survival (OS) was calculated from date of diagnosis to date of death from any cause, up to 130 months.

Countries

France

Outcome results